Inhibition of Human Sterol Δ7-Reductase and Other Postlanosterol Enzymes by LK-980, a Novel Inhibitor of Cholesterol Synthesis
Authors:
- Tina KorošecTKTina Korošec
- Matej SeliškarMSMatej Seliškar
- Ingemar BjorkhemIBIngemar Bjorkhem
- Katalin MonostoryKMKatalin Monostory
- Pal SzaboPSPal Szabo
- Jean-Marc PascussiJPJean-Marc Pascussi
- Ales BeličABAles Belič
- Uroš UrlebUUUroš Urleb
- Darko KocjanDKDarko Kocjan
- Damjana RozmanDRDamjana Rozman
- 1 January 2011
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (1) , 39-46
Abstract
Novel potential inhibitors of the postsqualene portion of cholesterol synthesis were screened in HepG2 cells. 2-(4-Phenethylpiperazin-1-yl)-1-(pyridine-3-yl)ethanol (LK-980) was identified as a prospective compound and was characterized further in cultures of human primary hepatocytes from seven donors. In vitro kinetic measurements show that the half-life of LK-980 is at least 4.3 h. LK-980 does not induce CYP3A4 mRNA nor enzyme activity. Target prediction was performed by gas chromatography-mass spectrometry, allowing simultaneous separation and quantification of nine late cholesterol intermediates. Experiments indicated that human sterol Δ7-reductase (DHCR7) is the major target of LK-980 (34-fold increase of 7-dehydrocholesterol), whereas human sterol Δ14-reductase (DHCR14), human sterol Δ24-reductase (DHCR24), and human sterol C5-desaturase (SC5DL) represent minor targets. In the absence of purified enzymes, we used the mathematical model of cholesterol synthesis to evaluate whether indeed more than a single enzyme is inhibited. In silico inhibition of only DHCR7 modifies the flux of cholesterol intermediates, resulting in a sterol profile that does not support experimental data. Partial inhibition of the DHCR14, DHCR24, and SC5DL steps, in addition to DHCR7, supports the experimental sterol profile. In conclusion, we provide experimental and computational evidence that LK-980, a novel inhibitor from the late portion of cholesterol synthesis, inhibits primarily DHCR7 and to a lesser extent three other enzymes from this pathway.Keywords
This publication has 33 references indexed in Scilit:
- Perspectives of the non-statin hypolipidemic agentsPharmacology & Therapeutics, 2010
- Drug Interaction Potential of 2-((3,4-Dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the Novel Nonstatin-Type Cholesterol-Lowering AgentDrug Metabolism and Disposition, 2009
- Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibratesInternational Journal of Cardiology, 2008
- Drug Insight: translating evidence on statin therapy into clinical benefitsNature Clinical Practice Neurology, 2008
- Current questions regarding the use of statins in patients with coronary heart diseaseInternational Journal of Cardiology, 2007
- Dehydroepiandrosterone Induces Human CYP2B6 through the Constitutive Androstane ReceptorDrug Metabolism and Disposition, 2007
- Statins and clinical outcomes in heart failureClinical Science, 2007
- HEM dysplasia and ichthyosis are likely laminopathies and not due to 3β-hydroxysterol Δ14-reductase deficiencyHuman Molecular Genetics, 2007
- Sterol stringency of proliferation and cell cycle progression in human cellsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- Reversible inactivation of 3-hydroxy-3-methylglutaryl coenzyme a reductase: Reductase kinase and mevalonate kinase are separate enzymesBiochemical and Biophysical Research Communications, 1982